CLOUDBREAK-B

Cloudbreak Pharma (2592.HK) experienced a single-sided decline during the morning session, opening lower at HKD 1.160 and continuously weakening, with the intraday low hitting HKD 1.080 before closing at HKD 1.085, down 7.26%, with turnover of only HKD 116,500 indicating thin trading. The company recently completed a series of share placements, with a next-day disclosure return on August 6 showing a 41.7 million share increase in share capital, following a 22,848,000 share increase in July, and the continued dilution is pressuring the stock. Meanwhile, despite R&D pipeline progress, Q4 2025 financials showed revenue of just HKD 875,224, down 97.79% YoY, and a net loss of HKD 283.4 million, widening 55.22% YoY, with a net profit margin of -32,376%, indicating deep fundamental weakness. The stock is now 88.67% below its 52-week high of HKD 9.58, and trades below both the 20-day MA of HKD 1.212 and the 60-day MA of HKD 1.238, though it has already declined 75.94% YTD, and the company did secure a share subscription agreement with ARC Group for up to US$15 million, providing some liquidity buffer.

Cloudbreak Pharma opened lower and extended losses to close the morning session 6.05% lower at HKD 1.16, driven by frequent capital activities including a share subscription agreement with ARC Group International for up to US$15 million and multiple prior equity disclosures, raising dilution concerns. The appointment of a new company secretary and authorized representative also drew market attention. Financially, Q4 2025 operating revenue plunged 97.79% YoY to just HKD 875,224, with an EPS loss of HKD 0.3381 showing no significant narrowing, underscoring challenging fundamentals. The stock has retreated 87.84% from its 52-week high of HKD 9.58 and is down 74.17% YTD, trading well below both the 20-day MA (HKD 1.249) and 60-day MA (HKD 1.252). However, the company's pipeline progress — including CBT-001 in Phase III MRCT, completed Phase I/II for CBT-009, and recent FDA clearance for CBT-358 — may offer medium-term support.

拨康视云制药午后开盘即跳空高开，并以 1.220 港元收盘，较前收 1.150 港元上涨 6.09%，日内波动区间为 1.130 至 1.220 港元，形成典型的低开高走形态。早盘成交清淡仅 6.6 万股，但下午开盘后成交量激增至约 140.95 万股，推动股价快速拉升，主因是公司获得美国 FDA 安全许可，启动 CBT-358 的临床研究，同时与 ARC Group International 签署最高 1500 万美元的股份认购协议。不过，当前股价仅略高于 20 日均线（1.286 港元）和 60 日均线（1.29 港元），且距 52 周高点 9.58 港元仍下跌 87.27%，今年迄今跌幅达 72.95%，显示估值修复压力较大。近期公司还从 Cedar Wealth 仲裁案中脱身，但仍面临持续亏损——最近季度净利润亏损约 2.83 亿港元，营收同比骤降 97.79%。

Cloudbreak Pharma staged a rebound today, closing at HKD 1.33, up 0.76% from the open of HKD 1.32, despite an intraday low of HKD 1.25. The stock, down 86.12% from its 52-week high of HKD 9.58 and 70.51% YTD, rallied in the afternoon session on FDA clearance to begin a Phase 3 clinical trial for CBT-001 and a share subscription agreement with ARC Group International for up to USD 15 million, reaching an intraday high of HKD 1.35. The recovery brought the price close to the 60-day moving average of HKD 1.34. However, the company reported a net loss of HKD 283.36 million in Q4 2025, widening 55.22% YoY, with revenue plummeting 97.79% YoY, underscoring persistent fundamental weakness.

Cloudbreak Pharma opened lower and extended losses in the morning session, closing at HK$1.240, down 7.46%, driven by lingering negative sentiment from prior sharp declines. The intraday range was between HK$1.340 and HK$1.240, with thin trading volume of only 26,500 shares. The stock has been under pressure due to judicial preservation orders and the lifting of lock-up restrictions, with recent events like shareholder meeting resolutions and a US$15 million share subscription agreement with ARC Group failing to provide support. Financially, operating revenue in Q4 2025 plunged 97.79% YoY to HK$875,224, while the net loss remained substantial at HK$283 million, with a net profit margin of -32,376%. The current price is 87.06% below its 52-week high of HK$9.58 and has fallen below the 60-day moving average of HK$1.339, though it remains slightly above the 20-day MA of HK$1.242. However, the company's lead product CBT-001 is in Phase III trials, and a survey indicates strong demand for prescription treatment among pinguecula patients, offering potential long-term catalysts.